PapersFlow Research Brief
Melanoma and MAPK Pathways
Research Guide
What is Melanoma and MAPK Pathways?
Melanoma and MAPK pathways refer to the study of mammalian MAP kinase signaling cascades, particularly BRAF and ERK pathway mutations driving melanoma proliferation, and targeted therapies addressing oncogenic activation and resistance.
The field encompasses 50,615 papers on MAP kinase pathways in cancer, with a focus on BRAF gene mutations prevalent in melanoma. Key research identifies BRAF V600E as a driver mutation targeted by inhibitors like vemurafenib, improving survival in mutated melanoma patients. Studies also examine immune checkpoint inhibitors such as nivolumab and ipilimumab, which extend progression-free survival in untreated metastatic melanoma.
Topic Hierarchy
Research Sub-Topics
BRAF Inhibitors in Melanoma
This sub-topic covers small molecule inhibitors targeting BRAF V600E mutations including vemurafenib and dabrafenib, focusing on clinical efficacy, pharmacokinetics, and combination strategies. Researchers study resistance emergence and biomarker development.
MEK Inhibitor Combination Therapies
This sub-topic examines MEK inhibitors like trametinib combined with BRAF inhibitors to delay resistance and improve progression-free survival in BRAF-mutant melanoma. Researchers investigate optimal dosing, toxicity profiles, and molecular predictors.
MAPK Pathway Resistance Mechanisms
This sub-topic addresses acquired resistance via MAPK reactivation through BRAF amplification, MEK mutations, or parallel pathway activation in melanoma. Researchers utilize cell line screens, patient-derived models, and single-cell sequencing.
ERK Signaling Dynamics in Melanoma
This sub-topic focuses on feedback regulation, scaffold proteins, and nuclear translocation controlling ERK activation duration and localization in melanoma cells. Researchers employ live-cell imaging and mathematical modeling of pathway kinetics.
MAPK Pathway and Melanoma Immunity
This sub-topic investigates MAPK inhibition effects on tumor immunogenicity, antigen presentation, and T-cell exclusion in the melanoma microenvironment. Researchers study combination immunotherapy rationale and biomarkers of response.
Why It Matters
Targeted therapies against MAPK pathways have transformed melanoma treatment outcomes. In the BRIM-3 trial, vemurafenib improved overall and progression-free survival rates in previously untreated patients with BRAF V600E-mutated melanoma (Chapman et al., 2011, "Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation"). Combined nivolumab and ipilimumab yielded significantly longer progression-free survival than ipilimumab monotherapy in untreated metastatic melanoma, especially in PD-L1-negative tumors (Larkin et al., 2015, "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma"). These advances highlight MAPK inhibition and immunotherapy as critical for managing mutation-driven cancers, informing combination strategies to overcome resistance as detailed in resistance mechanism studies.
Reading Guide
Where to Start
"Mutations of the BRAF gene in human cancer" by Davies et al. (2002), as it foundational identifies BRAF mutations driving MAPK signaling in melanoma and other cancers, providing essential genetic context before therapy papers.
Key Papers Explained
Davies et al. (2002) "Mutations of the BRAF gene in human cancer" establishes BRAF V600E as a key oncogenic driver. Chapman et al. (2011) "Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation" builds on this by validating BRAF inhibition clinically. Larkin et al. (2015) "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma" extends to immunotherapy combinations, addressing limitations in BRAF-wildtype cases. Barretina et al. (2012) "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity" supports preclinical modeling across these therapies. Holohan et al. (2013) "Cancer drug resistance: an evolving paradigm" connects them by explaining resistance mechanisms.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research emphasizes resistance to BRAF/MEK inhibitors and immunotherapy combinations in melanoma. Frontiers involve modeling sustained ERK activation (Marshall, 1995) with CCLE data (Barretina et al., 2012) to predict outcomes. No recent preprints available, but foundational signaling cascades (Chang and Karin, 2001) guide ongoing pathway analysis.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Mutations of the BRAF gene in human cancer | 2002 | Nature | 10.5K | ✓ |
| 2 | The Cancer Cell Line Encyclopedia enables predictive modelling... | 2012 | Nature | 8.3K | ✕ |
| 3 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated ... | 2015 | New England Journal of... | 8.0K | ✓ |
| 4 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E... | 2011 | New England Journal of... | 7.6K | ✓ |
| 5 | Pembrolizumab versus Ipilimumab in Advanced Melanoma | 2015 | New England Journal of... | 5.7K | ✓ |
| 6 | Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis | 1995 | Science | 5.3K | ✕ |
| 7 | Nivolumab in Previously Untreated Melanoma without <i>BRAF</i>... | 2014 | New England Journal of... | 5.3K | ✓ |
| 8 | Mammalian MAP kinase signalling cascades | 2001 | Nature | 5.1K | ✕ |
| 9 | Specificity of receptor tyrosine kinase signaling: Transient v... | 1995 | Cell | 4.6K | ✓ |
| 10 | Cancer drug resistance: an evolving paradigm | 2013 | Nature reviews. Cancer | 4.4K | ✕ |
Frequently Asked Questions
What is the role of BRAF mutations in melanoma?
BRAF gene mutations, particularly V600E, drive oncogenic signaling in human cancers including melanoma. Davies et al. (2002) identified these mutations in "Mutations of the BRAF gene in human cancer". This activates the MAPK pathway, promoting cell proliferation targeted by specific inhibitors.
How does vemurafenib treat BRAF-mutated melanoma?
Vemurafenib inhibits BRAF V600E, improving overall and progression-free survival in untreated patients. Chapman et al. (2011) reported these results in the BRIM-3 trial in "Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation". It addresses MAPK pathway activation specific to mutated tumors.
What are the benefits of nivolumab-ipilimumab combination in melanoma?
The combination prolongs progression-free survival over ipilimumab alone in untreated metastatic melanoma. Larkin et al. (2015) showed superior efficacy in PD-L1-negative tumors in "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma". It leverages PD-1 and CTLA-4 blockade for enhanced immune response.
How do MAP kinases regulate apoptosis in cancer?
ERK promotes survival while JNK-p38 induces apoptosis in neuronal and cancer cells. Xia et al. (1995) demonstrated opposing effects in "Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis". This balance influences melanoma cell fate via MAPK signaling.
What causes resistance to cancer therapies targeting MAPK?
Resistance evolves through pathway reactivation and adaptive mechanisms in MAPK-driven cancers. Holohan et al. (2013) reviewed this in "Cancer drug resistance: an evolving paradigm". It impacts melanoma treatments like BRAF and MEK inhibitors.
What is the Cancer Cell Line Encyclopedia's role in MAPK research?
The CCLE enables predictive modeling of drug sensitivity in cancer cell lines, including melanoma models. Barretina et al. (2012) established this resource in "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity". It supports testing MAPK-targeted therapies.
Open Research Questions
- ? How do combination BRAF and MEK inhibitors prevent resistance in BRAF-mutated melanoma?
- ? What mechanisms underlie differential ERK versus JNK-p38 activation in melanoma immune evasion?
- ? Which genetic interactions beyond BRAF V600E sustain MAPK signaling in resistant melanoma cells?
- ? How do immune checkpoint inhibitors interact with MAPK pathway inhibition in PD-L1-negative melanoma?
- ? What role do sustained versus transient ERK activation play in melanoma metastasis?
Recent Trends
The field maintains 50,615 works with sustained focus on BRAF mutations and therapies, as no growth rate data or recent preprints/news are available.
High-impact papers like Larkin et al. continue to inform combination immunotherapy, building on Davies et al. (2002) BRAF discovery without new metrics reported.
2015Research Melanoma and MAPK Pathways with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Melanoma and MAPK Pathways with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers